The release of a Cochrane review showing high dose oral NSAIDs can slow the progression of lung damage in people with cystic fibrosis is unlikely to change clinical practice, says a leading Australian respiratory physician and researcher. Associate Professor Sarath Ranganathan, director of Respiratory and Sleep Medicine at the Royal Children’s Hospital in Melbourne, and ...
Cystic Fibrosis
Oral NSAIDs promising on paper, but CF clinicians wary
25 Apr 2016